# Maestros Elect (NSE: METSL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/METSL · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹76 Cr, it ranks 2815th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Devices.

Its return on equity was 17.2% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹12 Cr (+51.3% year on year) and net profit ₹2 Cr (+173.3%), on a consolidated basis. Promoters held 63.90% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹76 Cr |
| ROE | 17.2% (FY26) |
| ROCE | 19.6% (FY26) |
| Debt to equity | 0.04 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹12 Cr | +51.3% | ₹2 Cr | +173.3% | ₹4.26 |
| Q3 FY26 | ₹11 Cr | +123.0% | ₹3 Cr | +272.6% | ₹4.93 |
| Q2 FY26 | ₹6 Cr | −19.4% | ₹1 Cr | −34.7% | ₹1.19 |
| Q1 FY26 | ₹10 Cr | +19.9% | ₹2 Cr | −14.0% | ₹2.78 |
| Q4 FY25 | ₹8 Cr | — | ₹1 Cr | — | ₹1.56 |
| Q3 FY25 | ₹5 Cr | +49.6% | ₹1 Cr | +284.2% | ₹1.32 |
| Q2 FY25 | ₹7 Cr | — | ₹1 Cr | — | ₹1.83 |
| Q1 FY25 | ₹9 Cr | — | ₹2 Cr | — | ₹3.23 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹29 Cr | ₹4 Cr |
| FY24 | ₹33 Cr | ₹5 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 63.90%
- Foreign institutions: 0.20%
- Non-institutions: 35.90%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Amwill Health](https://app.pivotnow.in/stock/AMWILL) | — | ₹89 Cr | — | — |
| [Modern Diagnost](https://app.pivotnow.in/stock/MDRC) | — | ₹81 Cr | — | — |
| [Bharat Immuno](https://app.pivotnow.in/stock/BIBCL) | — | ₹75 Cr | — | — |
| [Source Natural](https://app.pivotnow.in/stock/SOURCENTRL) | — | ₹70 Cr | — | — |
| [Asston Pharma](https://app.pivotnow.in/stock/APL) | — | ₹69 Cr | — | — |
| [Fervent Synergi](https://app.pivotnow.in/stock/FERVENTSYN) | — | ₹68 Cr | — | — |

## Questions and answers

### What is the market cap of Maestros Elect?

Maestros Elect's market capitalisation is ₹76 Cr (₹76 Cr) at the 22 Oct 2026 close, ranking 2815th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Maestros Elect?

Return on equity was 17.2% in FY26 and return on capital employed was 19.6% in FY26 (consolidated figures).

### Is Maestros Elect a debt-free company?

Maestros Elect is close to debt-free: its debt-to-equity ratio was 0.04 in FY26.

### What were Maestros Elect's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Maestros Elect reported revenue of ₹12 Cr, +51.3% year on year, and net profit of ₹2 Cr, +173.3% year on year.

### What is the shareholding pattern of Maestros Elect?

As of 30 Jun 2026: promoters 63.90%, foreign institutions 0.20%, non-institutions 35.90%.

### Who are Maestros Elect's competitors?

The listed Pharma & Healthcare companies closest to Maestros Elect by market cap are Amwill Health, Modern Diagnost, Bharat Immuno, Source Natural, Asston Pharma and Fervent Synergi.

### Is Maestros Elect a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Maestros Elect's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on METSL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.